Azepino[4,5-b]pyrano[3,2-e]indoles

A compound of formula (I):

• 26
• wherein:
• R1 is selected from the group consisting of H, C1-8alkyl and C1-8alkylenearyl;
• each R2, independently, is selected from the group consisting of halo, C1-8alkyl, C1-8alkoxy, aryl, and OH;
• R3 is selected from the group consisting of hydrogen, C1-8alkyl, aryl, heteroaryl, C(═O)Ra, C(═O)ORa, C(═O)NRaRb, C(═O)SRa, C(═S)NRaRb, SO2Ra, SO2NRaRb, S(═O)Ra, S(═O)NRaRb, C(═O)NRaC1-6alkyleneORa, C(═O)NRaC1-6alkyleneHet, C(═O)C1-6alkylenearyl, C(═O)C1-6alkyleneheteroaryl, C1-6alkylenearyl, C1-6alkyleneheteroaryl, C1-6alkyleneHet, C1-6alkyleneC(═O)C1-6alkylenearyl, C1-6alkyleneC(═O)C1-6alkyleneheteroaryl, C1-6alkyleneC(═O)Het, C1-6alkyleneC(═O)NRaRb, C1-6alkyleneNRaC(═O)Ra, C1-6alkyleneOC1-6alkyleneORa, C1-6alkyleneNRaRb, C1-6alkyleneC(═O)ORa, C1-6alkyleneOC1-6alkyleneC(═O)ORa, C1-6alkyleneC(═O)aryl, C1-6alkyleneC(═O)heteroaryl, C1-6alkyleneOC1-6alkylenearyl, C1-6alkyleneOC1-6alkyleneheteroaryl, C1-6alkyleneOC1-6alkyleneHet, C1-6alkyleneSRa, C1-6alkyleneSO2Ra, C1-6alkyleneS(═O)R1;
• C1-6alkyleneSO2NRaRb, and C1-6alkyleneNSO2Ra;
• each R4, independently, is selected from the group consisting of halo, OH, CN, NO2, CF3, CF3O, NRaRb, C1-8alkyl, C1-8alkoxy, C1-8alkanoyl, C1-8alkoxycarbonyl, C1-8alkanoyloxy, aryl, heteroaryl, C1-6alkylenearyl, and C1-6alkyleneheteroaryl;
• each R5, independently, is selected from the group consisting of halo, C1-8alkyl, C1-8alkoxy, and OH;
• m is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
• n is 0, 1, 2, 3, 4, 5, or 6;
• p is 0, 1, or 2;
• bond a and bond b represented by ---- are each independently a single bond or a double bond;
• Ra and Rb, independently, are selected from the group consisting of hydrogen, C1-8alkyl, aryl, heteroaryl, arylC1-3alkyl, heteroarylC1-3alkyl, C1-3alkylenearyl, C1-3alkyleneheteroaryl, and Het;
• or a pharmaceutically acceptable salt or solvate thereof.